Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

11.99
-0.4500-3.62%
Pre-market: 11.98-0.0100-0.08%08:00 EST
Volume:860.24K
Turnover:10.33M
Market Cap:770.05M
PE:-14.89
High:12.53
Open:12.32
Low:11.85
Close:12.44
52wk High:19.05
52wk Low:5.90
Shares:64.22M
Float Shares:64.22M
Volume Ratio:1.03
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8052
EPS(LYR):-2.7663
ROE:-10.17%
ROA:-6.30%
PB:1.36
PE(LYR):-4.33

Loading ...

Arvinas Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
Feb 20

Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
Feb 20

Arvinas Inc. Files Initial Beneficial Ownership Statement for President and CEO Randy Teel

Reuters
·
Feb 19

Arvinas Inc. to Report Financial Results and Provide Corporate Update

Reuters
·
Feb 17

Press Release: Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Dow Jones
·
Feb 17

Arvinas Sets CEO Base Salary at $680,000 With Equity and Bonus Package

Reuters
·
Feb 12

Arvinas Appoints Randy Teel as President and CEO

Reuters
·
Feb 12

Arvinas Inc - John Houston to Continue as Board Member and Consultant

THOMSON REUTERS
·
Feb 12

Arvinas Inc - Briggs Morrison Elected as Chair of Arvinas Board

THOMSON REUTERS
·
Feb 12

Arvinas Inc - John Houston Retires as President and CEO of Arvinas

THOMSON REUTERS
·
Feb 12

Press Release: Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Dow Jones
·
Feb 12

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

Reuters
·
Feb 10

Arvinas Raised to Buy From Neutral by Citigroup

Dow Jones
·
Jan 06

Citigroup Upgrades Arvinas to Buy From Neutral, Adjusts Price Target to $15 From $10

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Arvinas Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025

Arvinas Announces Phase 1 Trial of ARV-393 and Glofitamab Combination for Lymphoma

Reuters
·
Dec 06, 2025

Arvinas Highlights Vepdegestrant Breast Cancer Data at 2025 SABCS

Reuters
·
Nov 24, 2025

Arvinas Q3 Revenue USD 41.9 Million

Reuters
·
Nov 20, 2025